References
- Woo J, Ho Sc, Chan SG, et al. An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population. Journal of Epidemiology and Community Health 1997; 51: 486–489
- List of charges. Hong Kong Government Gazette. S.S.No.4, 13/2003.
- Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. Journal of Rheumatology 1989; 16: 861–884
- Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28–33.
- Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis and Rheumatism 2003; 48: 2750–2762
- Ruof J, Hülsemann JL, Mittendorf T, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on the healthcare payer's data sources. Annals of the Rheumatic Diseases 2003; 62: 544–549
- Lee VWY, Chan WK, Lam NLC, et al. Cost of acute myocardial infarction in Hong Kong. Disease Management & Health Outcomes 2005; 13: 281–285
- The Hong Kong Hospital Authority. International comparison of population and health statistics. Available at: http://www.ha.org.hk [last accessed 21 October 200].
- Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Annals of Internal Medicine 1999; 130: 478–486
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRCAT Study Group. Lancet 1999; 354: 1932–1939
- Lyseng-Williamson F. Infliximab. A pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22: 107–132
- Chan TYK, Critchley JAJH, Lau JTF, et al. The relationship between upper gastrointestinal hemorrhage and drug use: a case control study. Journal of Clinical Pharmacology and Therapeutics 1996; 34: 304–308
- You JHS, Lee KKC, Chan TYK, et al. Arthritis treatment in Hong Kong—cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Alimentary Pharmacology & Therapeutics 2002; 16: 2089–2096
- Cooper NJ, Mugford M, Symmons DPM, et al. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology 2002; 41: 767–774
- Verstappen SMM, Verkleij H, Bijlsma JWJ, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2004; 63: 817–824
- Lapsley HM, Tribe LM, Cross MJ, et al. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Annals of the Rheumatic Diseases 2002; 61: 818–821
- Woo J, Cockram C. Cost estimate for chronic diseases. Disease Management and Health Outcomes 2000; 8: 29–41